"Never doubt that a small group of thoughtful, committed citizens can change the world; indeed, it's the only thing that ever has." - Margaret Mead You are thoughtful, and committed. You will change this world! https://t.co/OFGN223bPa

👩⚕️🧑⚕️ RheumIQ is here. Each week, challenge yourself with 5 quick questions on the latest in rheumatology. ✅ Fast ✅ Evidence-based ✅ Competitive ➡️ Test your RheumIQ today: https://t.co/OjhbnTjFyZ https://t.co/JrPfPn3N8n

MUC5 mutations not in SSc-ILD. Study of 2363 SSc-ILD, 3526 SSc w/o ILD & 15076 controls. They found no assoc w/ MUC5B promoter variant & SSc-ILD. (Suggesting ILD pathogenic mechanisms differ between RA and SSc) https://t.co/bBq52X0Mwq https://t.co/QdUzra1fnj

September is Rheumatic Disease Awareness Month! ARP president Adam Goode, Encourages Physical Activity During September - exercise, move, & get strong!! https://t.co/HhdnJdvBjR https://t.co/BuqTAMJaqN

Wait! FDA approved the Chikungunya Virus Vaccine 2 yrs ago, but just pulled the vaccine, Ixchiq, citing serious safety concerns (specifically CBER reports of >20 serious adverse events, including 21 hospitalizations, 3 deaths, w/ 1 fatality directly linked to vaccine-derived https://t.co/k5wBtsGVIs

New #therapy in #SLE #lupus https://t.co/TPeKxfw9hq

What Is Lyme Disease? JAMA Patient education handout. Lyme disease is the most common tick-borne infection in the US. A bite from infected Ixodes scapularis ticks can transmit the bacterium Borrelia burgdorferi, which causes Lyme disease. https://t.co/a8eMdAy0bi https://t.co/Jrj4Eiuy24

Recombinant zoster vaccine effective in #SLE without flare. Retrospective Medicare & commercial claims data on pts given 2 RZV doses, matched 1:4 to unVAX. 3592 pts F?u ~1.5 yrs. Vax effectiveness 70% in Medicare; 54% commercial. SLE flare rates HR 0.91& 0.94. https://t.co/bcEwtzFDvy

Metanalysis shows patients w/ psoriasis have signif. higher risk (2-2.5 fold) of metabolic syndrome compared to the general population, RA or spondylitis patients. Comparing PsO to PsA there is no difference (PsA also has a high riskof MetS). https://t.co/gO3IomfP53 https://t.co/Ov2UHV2mN6

Celltrions tocilizumab biosimilar, tocilizumab-anoh (Avtozma, CT-P47), had similar efficacy when switching from reference tocilizumab (Actemra; Genentech) in a study of 444 RA patients x 52 wks. https://t.co/7aAyuUkZJ9 https://t.co/kJUrRkhstb